ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Core Viewpoint - ImmunityBio, Inc. is facing a securities fraud class action lawsuit due to a significant stock decline of 21% following an FDA warning regarding misleading advertising related to its cancer treatment, Anktiva [1][4]. Company Overview - ImmunityBio, Inc. (NasdaqGS: IBRX) is under scrutiny for failing to disclose material information during the class period from January 19, 2026, to March 24, 2026 [3][5]. - The company's stock price fell by $1.98, closing at $7.42 per share on March 24, 2026, after the FDA's warning letter was made public [4]. Legal Proceedings - Investors who suffered substantial losses have until May 26, 2026, to file lead plaintiff applications in the ongoing class action lawsuit against ImmunityBio [1][5]. - The lawsuit is currently pending in the United States District Court for the Central District of California, under the case name Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261 [5]. FDA Warning Details - The FDA issued a warning letter on March 13, 2026, indicating that ImmunityBio's promotional materials misrepresented Anktiva, suggesting it could cure and prevent all cancers, which violates the Federal Food, Drug, and Cosmetic Act [4].